Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model.

@article{Kao2017TelbivudineTF,
  title={Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model.},
  author={Jia-Horng Kao and Tarik Asselah and Xiao-guang Dou and Kamal A Hamed},
  journal={Journal of gastroenterology and hepatology},
  year={2017},
  volume={32 1},
  pages={73-81}
}
Hepatitis B virus (HBV) infection is one of the most serious health problems worldwide with a high risk for cirrhosis and liver cancer. Several antiviral agents have been approved for the treatment of chronic hepatitis B, leading to a rapid reduction in HBV DNA and normalization of serum alanine aminotransferase levels. Telbivudine, a potent inhibitor of HBV replication, has been shown to be well tolerated. Because of the emergence of drug resistance, optimization strategies for telbivudine… CONTINUE READING